Il-12 for radiation protection and radiation-induced toxicity mitigation
AssigneeNeumedicines, Inc.
InventorLena A. Basile
Life of this patent
Estimating the term…
Abstract
Aspects and embodiments of the instant disclosure provide therapeutic methods and compositions comprising inter-leukin 12 (IL-12) useful for treating radiation-induced damage in a subject. In particular, the instant disclosure provides methods and compositions for radiation protection and/or radiation toxicity mitigation for the treatment of acute radiation syndrome and radiation induced toxicity associated with the treatment of cutaneous T-cell lymphoma.
Claims33
A method of protecting a subject from system, organ, tissue, or cellular damage, following exposure of the subject to ionizing radiation, the method comprising:
- administering a therapeutically effective amount of a pharmaceutical composition comprising substantially isolated rIL-12 to the subject, whereby the system, organ, tissue, and/or cellular damage due to radiation is diminished.
(canceled)
-7. (canceled)
-11. (canceled)
-15. (canceled)
(canceled)
-23. (canceled)
25-26. (canceled)
-29. (canceled)
-36. (canceled)
A pharmaceutical composition comprising substantially isolated rIL-12 in a suitable formulation for delivery to a subject in need for the prevention of radiation-induced damage.
(canceled)
-43. (canceled)
-50. (canceled)
-87. (canceled)
Dependencies are inferred from the claim text.